VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer

Table 4 Univariate analysis of OS and PFS in EOC patients

Variable	Cases (N)	Media of OS	y ²	p	Media of PFS	y ²	p
Age			3.212	0.073		1.830	0.176
≤ 50 years	60	54			41
> 50 years	64	43			34
Menopausal status			0.076	0.782		0.069	0.793
Yes	78	48
No	46	51
Pathologic type			0.354	0.552		0.002	0.967
Serous carcinoma	80	43			41
Mucous and others	44	53			36
Histologic grade			26.047	0.000		5.636	0.018
G_1–2	49	85			48
G₃ or Undifferentiated	75	43			33
FIGO Stage			32.221	0.000		11.370	0.001
I–II	53	68			49
III–IV	71	39			33
LN metastasis			17.484	0.000		12.361	0.000
No	74	56			48
Yes	50	35			33
Residual disease			24.872	0.000		5.824	0.016
< 1 cm	94	54			41
≥ 1 cm	30	35			33
Patients’ response to chemotherapy			16.060	0.000		5.393	0.020
CR	87	53			40
PR, SD and PD	37	32			34
Tumor sensitivity to chemotherapy			10.502	0.001		13.085	0.000
Platinum sensitive	92	53			45
Platinum resistant and refractory	32	22			10
VEGF			29.685	0.000		1.945	0.163
Negative	72	58			41
Positive	52	32			34
SEMA4D			34.933	0.000		16.541	0.000
Negative	48	NR			49
Positive	76	41			31

FIGO International Federation of Gynecology and Obstetrics, NR not reached, CR complete response, PR partial response, SD stable disease, PD progressive disease

ISSN: 1689-1392